See analyst estimates and all valuation multiples for Biopharmaceuticals
Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
$688B | 14.0x | 35.8x | |
$378B | 4.2x | 11.9x | |
$371B | 6.5x | 14.4x | |
$280B | 6.3x | 12.9x | |
$242B | 3.5x | 8.8x | |
$224B | 4.0x | 11.9x | |
$223B | 3.5x | 8.2x | |
$210B | 4.1x | 10.1x | |
$202B | 5.9x | 10.3x | |
$167B | 2.6x | 6.9x | |
$144B | 5.0x | 12.1x | |
$144B | 3.0x | 14.8x | |
$128B | 2.7x | 9.1x | |
$120B | 10.6x | 53.8x | |
$84.7B | 2.1x | 6.0x | |
$81.6B | 5.3x | 15.9x | |
$71.4B | 7.7x | 18.0x | |
$69.9B | 2.3x | 9.0x | |
$62.1B | 7.9x | 16.1x | |
$62.0B | 2.7x | 9.4x | |
$56.3B | 1.1x | 5.3x | |
$46.6B | 6.0x | 20.6x | |
$44.9B | 7.3x | 25.4x | |
$39.1B | 9.9x | 39.2x | |
$34.0B | 2.7x | 14.9x | |
$30.7B | 1.9x | 6.5x | |
$24.6B | 9.4x | 30.3x | |
$22.2B | 1.5x | 5.0x | |
$22.2B | 1.4x | 6.2x | |
$21.7B | 2.2x | 6.5x | |
$21.1B | 2.2x | 6.3x | |
$19.8B | 1.6x | 7.5x | |
$19.7B | 6.9x | 7.4x | |
$19.0B | 1.8x | 9.2x | |
$15.0B | 1.9x | 7.7x | |
$14.1B | 8.1x | 21.7x | |
$13.5B | 158.1x | 334.1x | |
$13.3B | 20.1x | 35.8x | |
$12.8B | 4.0x | 15.4x | |
$12.6B | 4.9x | 13.1x | |
$12.5B | 9.3x | 28.5x | |
$12.2B | 2.2x | 16.0x | |
$11.1B | 1.7x | 5.7x | |
$10.8B | 7.5x | 28.6x | |
$10.7B | 1.9x | 10.5x | |
$10.6B | 2.8x | 10.3x | |
$10.4B | 4.0x | 17.0x | |
$10.2B | 3.9x | 10.6x | |
$9.8B | 3.7x | 12.5x | |
$9.3B | 6.8x | 435.2x | |
$9.2B | 2.9x | 7.5x | |
$9.0B | 25.7x | -383.3x | |
$8.6B | 1.4x | 12.9x | |
$8.4B | 31.7x | -318.6x | |
$8.4B | 2.8x | 6.8x | |
$8.4B | 3.4x | 12.2x | |
$8.3B | 7.8x | 12.4x | |
$8.1B | 2.2x | 6.0x | |
$7.9B | 2.4x | 7.1x | |
$7.6B | 1.9x | 8.0x | |
$7.4B | 2.0x | 9.5x | |
$7.4B | 4.4x | 12.9x | |
$7.3B | 0.2x | 3.4x | |
$7.1B | 9.4x | 36.3x | |
$7.1B | 1.8x | 9.7x | |
$7.0B | 16.2x | 21.7x | |
$6.7B | 1.7x | 6.9x | |
$6.4B | 4.2x | 21.3x | |
$6.3B | 2.0x | 7.5x | |
$6.2B | 1.2x | 9.8x | |
$6.0B | 3.4x | 17.1x | |
$5.8B | 4.6x | 13.7x | |
$5.8B | 6.7x | 13.5x | |
$5.6B | 1.7x | 7.3x | |
$5.6B | n/a | n/a | |
$5.6B | 3.9x | 59.9x | |
$5.2B | n/a | n/a | |
$5.2B | 2.1x | 7.8x | |
$5.2B | 11.8x | 38.8x | |
$5.0B | 2.1x | 5.7x | |
$5.0B | 2.4x | 8.8x | |
$5.0B | 1.5x | 6.5x | |
$4.8B | n/a | n/a | |
$4.7B | 7.7x | 26.6x | |
$4.7B | 1.6x | 7.3x | |
$4.6B | 10.3x | 25.2x | |
$4.5B | 2.9x | 15.9x | |
$4.2B | 12.3x | 54.3x | |
$4.2B | 9.9x | 26.3x | |
$3.9B | n/a | n/a | |
$3.9B | 5.4x | 18.5x | |
$3.8B | 6.2x | 14.5x | |
$3.8B | 7.1x | 25.9x | |
$3.8B | 2.5x | 9.4x | |
$3.8B | n/a | n/a | |
$3.7B | 34.0x | n/a | |
$3.5B | 2.7x | 8.1x | |
$3.5B | 2.6x | 9.1x | |
$3.4B | 11.3x | -28.0x | |
$3.2B | 12.3x | -23.4x | |
$3.0B | 2.4x | 9.0x | |
$3.0B | 1.5x | 10.0x | |
$2.9B | 5.8x | 21.5x | |
$2.9B | n/a | n/a | |
$2.8B | 1.8x | 9.2x | |
$2.8B | 7.5x | 23.1x | |
$2.7B | 3.4x | 12.8x | |
$2.7B | 7.4x | 41.9x | |
$2.7B | n/a | n/a | |
$2.6B | 6.2x | 20.1x | |
$2.6B | 4.3x | 15.9x | |
$2.6B | n/a | n/a | |
$2.5B | n/a | n/a | |
$2.5B | 4.1x | 15.5x | |
$2.5B | n/a | n/a | |
$2.4B | 3.1x | 16.1x | |
$2.3B | 5.5x | 15.9x | |
$2.3B | 2.2x | 10.6x | |
$2.3B | 302.9x | -9.0x | |
$2.2B | 8.3x | 16.7x | |
$2.1B | 1.9x | 9.8x | |
$2.1B | 2.9x | 15.1x | |
$2.0B | n/a | n/a | |
$2.0B | 14.5x | 35.2x | |
$2.0B | 3.0x | 11.8x | |
$1.9B | 3.4x | 8.2x | |
$1.9B | n/a | n/a | |
$1.9B | 14.8x | -20.5x | |
$1.8B | 40.1x | -90.5x | |
$1.7B | 14.5x | -27.5x | |
$1.7B | 7.4x | -16.4x | |
$1.7B | 354.3x | n/a | |
$1.7B | n/a | n/a | |
$1.7B | 4.4x | 12.4x | |
$1.6B | 2.2x | 5.6x | |
$1.5B | 2.4x | -65.7x | |
$1.5B | 2.3x | 3.7x | |
$1.5B | 4.1x | 16.7x | |
$1.5B | 3.6x | 17.9x | |
$1.5B | 9.6x | -20.0x | |
$1.4B | 21.5x | 89.5x | |
$1.4B | 6.0x | -12.0x | |
$1.3B | 2.1x | 8.4x | |
$1.3B | 12.3x | -25.6x | |
$1.3B | 4.9x | -7.4x | |
$1.3B | n/a | n/a | |
$1.3B | 24.7x | -13.3x | |
$1.3B | 0.6x | 3.6x | |
$1.3B | n/a | n/a | |
$1.3B | 3.3x | 14.3x | |
$1.3B | 1.4x | 5.8x | |
$1.3B | 6.6x | 86.0x | |
$1.2B | 1.7x | -12.2x | |
$1.2B | 2.2x | 8.5x | |
$1.2B | 2.5x | -69.1x | |
$1.2B | 1.0x | 4.0x | |
$1.1B | 3.2x | n/a | |
$1.1B | 2.4x | 16.0x | |
$1.1B | n/a | n/a | |
$1.1B | n/a | n/a | |
$1.1B | 0.5x | 4.8x | |
$1.0B | 4.7x | 19.7x | |
$1.0B | n/a | n/a | |
$982M | 19.4x | n/a | |
$966M | 2.8x | -85.5x | |
$936M | 3.2x | 21.8x | |
$934M | 9.5x | 242.4x | |
$917M | n/a | n/a | |
$888M | n/a | n/a | |
$879M | n/a | -5.7x | |
$840M | 3.9x | 86.1x | |
$827M | 22.1x | n/a | |
$810M | n/a | n/a | |
$803M | 0.8x | 4.5x | |
$799M | 1.4x | 6.9x | |
$786M | 20.6x | -122.8x | |
$742M | n/a | n/a | |
$739M | 3.1x | n/a | |
$723M | 17.6x | -2.1x | |
$713M | n/a | n/a | |
$713M | n/a | n/a | |
$700M | 4.3x | 21.3x | |
$690M | 758.8x | -7.0x | |
$689M | 2.6x | 4.5x | |
$680M | n/a | n/a | |
$671M | n/a | -3.3x | |
$670M | 3.5x | -144.2x | |
$670M | n/a | n/a | |
$664M | 2.0x | 6.8x | |
$633M | n/a | n/a | |
$631M | 5.9x | 28.2x | |
$618M | 1.7x | 12.4x | |
$614M | n/a | n/a | |
$607M | 1.4x | 6.4x | |
$600M | 5.2x | 7.5x | |
$591M | n/a | n/a | |
$591M | 6.1x | -4.4x | |
$582M | n/a | -2.8x | |
$574M | 30.2x | -214.7x | |
$540M | n/a | -6.5x | |
$532M | 6.5x | -4.0x | |
$531M | 2.2x | 9.7x | |
$517M | 254180.3x | -4.6x | |
$490M | 875.7x | -3.0x | |
$480M | 77.4x | n/a | |
$474M | 5.2x | 26.0x | |
$452M | 1.5x | -154.2x | |
$451M | n/a | n/a | |
$441M | n/a | n/a | |
$437M | n/a | n/a | |
$430M | n/a | n/a | |
$427M | 2.5x | n/a | |
$426M | n/a | n/a | |
$410M | 1.3x | 5.7x | |
$405M | n/a | -1.1x | |
$399M | n/a | -4.5x | |
$379M | 43.2x | -14.9x | |
$378M | 6.5x | 32.9x | |
$377M | 5.4x | -21.8x | |
$359M | 3.5x | -31.7x | |
$355M | 1.1x | 7.1x | |
$353M | 3.6x | -3.5x | |
$350M | n/a | n/a | |
$350M | 161.2x | -5.4x | |
$347M | n/a | -2.0x | |
$338M | n/a | -1.4x | |
$336M | 3.1x | -1.9x | |
$334M | n/a | n/a | |
$332M | 2.2x | 9.7x | |
$326M | n/a | -1.5x | |
$324M | n/a | n/a | |
$322M | 34.6x | -3.1x | |
$315M | n/a | n/a | |
$310M | 4.3x | 18.1x | |
$309M | 27.9x | -8.6x | |
$303M | 1.2x | 7.7x | |
$298M | 7.7x | -21.4x | |
$292M | 53.5x | n/a | |
$288M | 27.7x | -1.8x | |
$285M | 1.7x | 8.1x | |
$279M | 0.8x | 6.6x | |
$271M | 2.0x | 4.1x | |
$265M | n/a | n/a | |
$262M | n/a | n/a | |
$244M | 2.8x | -1.0x | |
$230M | n/a | n/a | |
$212M | n/a | n/a | |
$212M | n/a | -1.7x | |
$211M | n/a | n/a | |
$210M | 3.4x | 6.6x | |
$209M | 9.9x | -3.7x | |
$209M | 13854.7x | -2.0x | |
$208M | 31.8x | -1.0x | |
$207M | n/a | n/a | |
$199M | 7.8x | -4.6x | |
$194M | 4.6x | -20.1x | |
$193M | 1.4x | -1.0x | |
$182M | 12.0x | n/a | |
$178M | n/a | n/a | |
$174M | n/a | n/a | |
$173M | 1.4x | 28.9x | |
$173M | 2.8x | n/a | |
$166M | 1.7x | 5.3x | |
$165M | 3.9x | -1.7x | |
$159M | 2.5x | n/a | |
$157M | n/a | -1.5x | |
$157M | n/a | n/a | |
$152M | 1.8x | -4.8x | |
$152M | 28.9x | -3.4x | |
$149M | n/a | n/a | |
$143M | 1.0x | -1.0x | |
$142M | 8.4x | 15.3x | |
$140M | n/a | n/a | |
$134M | n/a | n/a | |
$129M | 2.7x | 13.3x | |
$127M | n/a | n/a | |
$121M | 35.1x | -3.4x | |
$111M | 16.7x | -3.6x | |
$105M | n/a | -0.6x | |
$99.9M | 2.6x | 2.6x | |
$98.2M | n/a | -1.1x | |
$96.7M | n/a | -0.7x | |
$96.6M | n/a | n/a | |
$95.0M | 66.7x | -0.3x | |
$93.9M | n/a | n/a | |
$91.7M | 16.8x | -2.0x | |
$89.6M | 0.8x | n/a | |
$87.4M | n/a | -0.8x | |
$85.6M | 23.1x | -2.8x | |
$82.0M | n/a | -2.7x | |
$78.5M | n/a | n/a | |
$78.4M | 36.7x | n/a | |
$72.2M | 339.5x | -4.8x | |
$69.1M | 6.9x | n/a | |
$59.9M | n/a | n/a | |
$55.6M | 14.8x | -28.3x | |
$55.5M | 2.2x | -0.3x | |
$54.6M | 0.4x | -0.5x | |
$54.3M | 17.3x | -0.3x | |
$53.7M | n/a | n/a | |
$50.1M | n/a | n/a | |
$45.7M | 10.8x | -1.8x | |
$40.9M | 8.2x | -5.0x | |
$38.0M | n/a | n/a | |
$34.2M | n/a | -0.3x | |
$33.1M | 7.8x | n/a | |
$33.0M | n/a | -1.5x | |
$30.7M | 1.3x | 7.9x | |
$29.5M | n/a | -0.3x | |
$29.2M | n/a | n/a | |
$29.0M | 5.1x | -2.9x | |
$28.4M | 2415.0x | n/a | |
$24.8M | n/a | n/a | |
$22.4M | n/a | n/a | |
$20.0M | n/a | n/a | |
$19.0M | 25.0x | -9.9x | |
$17.8M | n/a | n/a | |
$16.7M | n/a | n/a | |
$14.9M | n/a | n/a | |
$13.2M | n/a | n/a | |
$10.8M | n/a | n/a | |
$9.2M | 4.3x | -0.5x | |
$8.5M | 1.2x | -0.6x | |
$6.6M | n/a | n/a | |
$5.7M | 0.3x | -0.3x | |
$4.7M | n/a | n/a | |
$4.4M | 1.3x | -0.5x | |
$4.2M | n/a | -0.5x | |
$3.5M | 3.4x | -0.9x | |
$1.3M | n/a | n/a | |
$0.8M | n/a | n/a | |
$0.5M | n/a | -0.0x | |
$0.4M | n/a | n/a | |
-$9.0M | -0.9x | 0.7x | |
-$14.3M | n/a | 0.2x | |
-$14.8M | -0.6x | 0.1x | |
-$15.1M | -28.4x | 0.3x | |
-$16.1M | n/a | 0.9x | |
-$18.3M | -4.8x | 0.1x | |
-$31.3M | -7.5x | 0.5x | |
-$33.7M | n/a | n/a | |
-$39.5M | -1.2x | 0.8x | |
-$45.5M | -5.5x | 1.0x | |
-$52.2M | -0.2x | 0.2x | |
-$52.4M | -1.0x | 0.1x | |
-$53.7M | -28.6x | 0.6x | |
-$59.8M | n/a | n/a | |
-$64.0M | n/a | n/a | |
-$66.9M | -18.7x | 0.4x | |
-$69.0M | -1.8x | n/a | |
-$70.3M | -6.6x | n/a | |
-$71.2M | -82.0x | 0.8x | |
-$73.3M | -34.5x | 0.8x | |
-$93.9M | -0.4x | 1.1x | |
-$94.8M | -55.4x | 1.7x | |
-$109M | n/a | 0.8x | |
-$114M | n/a | 0.7x | |
-$118M | n/a | 2.3x | |
-$120M | n/a | 0.7x | |
-$134M | -202.5x | n/a | |
-$170M | n/a | 1.6x | |
-$173M | -9.8x | 0.8x | |
-$175M | n/a | 1.2x | |
-$213M | -256.9x | 1.1x | |
-$214M | n/a | 2.8x | |
-$217M | n/a | 0.7x | |
-$277M | -3.7x | 1.7x | |
-$278M | -245.6x | 1.4x | |
-$323M | -38.1x | 0.9x | |
-$1.8B | -5.9x | 11.5x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Biopharmaceuticals